German Build Pharmaceutical Plant Rp1 Trillion Worth

jaysonhyd   May 24, 2016  

Germany will build a pharmaceutical factory in Indonesia with an investment of Rp 1 trillion (100 million U.S. dollars), because the pharmaceutical industry prospects are quite bright with the large number of residents supported.
“The pharmaceutical plant will produce intravenous fluids and injectable medications that are built in two phases to be completed within the next two years,” said President Director of PT B Braun Medical Indonesia Manogaran in Jakarta on Friday.
Menuru him, at the initial phase of the plant which was built in an area of ​​19 hectares that will have a production capacity of 75 million units per year, and 150 million units in the second phase.
“The pharmaceutical industry in the country is currently growing, because the construction of the plant in order to meet the needs of the wider community is considered very precise. Presence factory We are optimistic that the market will respond well,” he said.
Asked about the investment fund, he said, the fund 100 percent of the B. Braun instead of loans.
“We have the funds to invest in Indonesia,” he said.
Manogaran said, 75 million units of production was around 50 million to meet the needs of domestic and 25 million more for export.
“In the second phase of 150 million units, about 75 million units for export to other countries such as neighbor and Europe,” he said.
He added that the first operational employed about 500 people and will increase up to 800 people at the second stage.
“We will make Jakarta as a training center to prepare an integrated Indonesian experts to contribute in the factories B Braun. We also expect the presence of this plant will be more beneficial to the community especially the Asia Pacific Indonesia can enjoy better health services and affordable, “he said.
Meanwhile, the Board of Director Melsunger B Braun AG, Dr. Meinrad Lugan said, as the pharmaceutical and medical device company that has been supporting the hospital and healthcare industry in the world B Braun continues to innovate to provide products products affordable world-class standards.
“Given the strategic development of Indonesia, the German company committed to make Indonesia as a Center of Excellence for the Asia Pacific region,” he said.
He said, B Braun wanted to help reduce the risk of airborne contamination, bacteria and on bacteria, because it is made of fluid infusion which is the main product used as a basis for patient care.
“For the design of the bottle and technology is an important aspect in addition to the content to be packaged better,” he said.
Advisor to the Minister of Finance and Community Development Division Ministry of Health, Dr Yusharman said investment in the pharmaceutical industry today dalama country desperately needed.
“Because it’s a plan B Braun to build a pharmaceutical factory in Indonesia immediately supported,” he said.
The Government, he added very grateful for the investment made by the German pharmaceutical company.
“Because of his presence will provide support for the need for intravenous fluids is necessary to program the Social Security Agency (BPJS),” he said.
According to him, the Indonesian market in 2013 will require intravenous fluids as much as 100 million units per year and in 2020 will increase to 200 million units per year.
“B Braun also has a research and development center sharing, as well as to educate the Indonesian public, it makes me more optimistic,” he said.